Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...

Novartis is in Chicago for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and has brought along an interactive experience for the weekend. The Swiss drugmaker is rolling out its ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b maintenance therapy confers no additional benefit over observation alone ...

Unlike patients presenting at diagnosis with major route karyotypes of chronic myeloid leukemia (CML), those presenting with balanced or unbalanced minor route karyotype do not suffer worse prognosis ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...